Extension Study Following the Studies MT-1186-A03 or A04 to Evaluate the Safety of Oral Edaravone in Subjects With ALS
| 대상 질환 | ALS |
|---|---|
| 임상 단계 | 3상 |
| 스폰서 | Shionogi |
| 상태 | 완료 |
| 참여자 수 | 15 명 |
| 중재(약물) | MT-1186 |
| 시작일 | 2022년 10월 26일 |
| 완료일 | 2023년 6월 27일 |
| 결과 공개일 | 2025년 2월 3일 |
요약
The purpose of this study is to evaluate the safety of oral edaravone at a dose of 105 mg administered once daily for 10 days out of a 14-day period, followed by a 14-day drug-free period. This study will be continued until the earlier date when oral edaravone is commercially available at each site in Japan or August 2023.
Number of Patients With AEs and Adverse Drug Reactions
| MT-1186 | 6 Participants |
|---|---|
| MT-1186 | 0 Participants |
BENITIONS에서 보기 ClinicalTrials.gov 원문 보기
같은 질환의 다른 임상
- Expanded Controlled Study of Safety and Efficacy of MCI-186 in Patients With Amyotrophic L — Shionogi
- Efficacy and Safety Study of MCI-186 for Treatment of Amyotrophic Lateral Sclerosis (ALS) — Shionogi
- Efficacy and Safety Study of MCI-186 for Treatment of Amyotrophic Lateral Sclerosis (ALS) — Shionogi
- Phase 3 Study of MCI-186 for Treatment of Amyotrophic Lateral Sclerosis — Shionogi
- Efficacy and Safety Study of Oral Edaravone Administered in Subjects With ALS — Shionogi
- Safety Extension Study of Oral Edaravone Administered in Subjects With Amyotrophic Lateral — Shionogi